Amphastar Pharmaceuticals Gross Profit 2012-2024 | AMPH

Amphastar Pharmaceuticals gross profit from 2012 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Amphastar Pharmaceuticals Annual Gross Profit
(Millions of US $)
2023 $351
2022 $249
2021 $200
2020 $143
2019 $132
2018 $107
2017 $91
2016 $104
2015 $77
2014 $51
2013 $87
2012 $90
2011 $28
2009 $48
Amphastar Pharmaceuticals Quarterly Gross Profit
(Millions of US $)
2024-06-30 $95
2024-03-31 $90
2023-12-31 $96
2023-09-30 $108
2023-06-30 $73
2023-03-31 $74
2022-12-31 $71
2022-09-30 $59
2022-06-30 $63
2022-03-31 $56
2021-12-31 $56
2021-09-30 $51
2021-06-30 $47
2021-03-31 $45
2020-12-31 $37
2020-09-30 $37
2020-06-30 $33
2020-03-31 $37
2019-12-31 $33
2019-09-30 $35
2019-06-30 $32
2019-03-31 $31
2018-12-31 $35
2018-09-30 $29
2018-06-30 $26
2018-03-31 $17
2017-12-31 $20
2017-09-30 $21
2017-06-30 $27
2017-03-31 $23
2016-12-31 $20
2016-09-30 $28
2016-06-30 $32
2016-03-31 $25
2015-12-31 $33
2015-09-30 $18
2015-06-30 $13
2015-03-31 $13
2014-12-31 $12
2014-09-30 $12
2014-06-30 $15
2014-03-31 $13
2013-12-31 $20
2013-09-30 $20
2013-06-30 $27
2013-03-31 $20
2012-12-31 $52
2012-09-30 $57
2012-06-30 $49
2012-03-31 $46
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.469B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00